Physician profile
Jerry Chang
NPI 1518136027
$13,582.76
in general payments reported to CMS, 2019-2025
13 companies · $1,753 in 2025
The $1,753 reported for 2025 was more than what 81% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,388 · 2020: $545 · 2021: $1,604 · 2022: $2,744 · 2023: $1,904 · 2024: $3,644 · 2025: $1,753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,501 · Grant: $1,381 · Travel and Lodging: $1,366 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $53.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,500.95 |
| Grant | $1,380.95 |
| Travel and Lodging | $1,366.11 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $3,283.10 | 2023-2025 | Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Cap |
| Sientra, INC. | $3,242.14 | 2019-2022 | |
| Allergan, INC. | $1,917.05 | 2019-2022 | |
| Abbvie INC. | $1,586.48 | 2023-2025 | Natrelle Saline-Filled Breast Implants, Alloderm |
| Innovation Technologies INC | $1,184.93 | 2022-2025 | Irrisept |
| Davol INC. | $674.49 | 2022-2025 | Phasix Mesh |
| Mentor Worldwide LLC | $543.14 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer, Mentor Cpx 2 Breast Tissue Expander, Artoura Breast Tissue Expander |
| Motiva USA, LLC | $476.69 | 2025 | |
| Tela Bio, INC. | $322.76 | 2024-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Musculoskeletal Transplant Foundation INC. | $143.64 | 2021-2025 | |
| Tepha INC | $137.10 | 2019 | |
| Galderma Laboratories, L.P. | $51.59 | 2020 | |
| Smith+Nephew, INC. | $19.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.